<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="77666"><DrugName>rintatolimod (intranasal, influenza/Ebola virus infection), Hemispherx Biopharma</DrugName><DrugNamesKey><Name id="42764107">Ampligen</Name><Name id="42910542">rintatolimod</Name></DrugNamesKey><DrugSynonyms><Name><Value>Ampligen</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Ampligen (DOGS delivery technology), Hemispherx</Value></Name><Name><Value>poly(I)-poly(C12U)</Value></Name><Name><Value>rintatolimod</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>rintatolimod (intranasal, influenza virus infection), Hemispherx Biopharma</Value></Name><Name><Value>atvogen</Value></Name><Name><Value>rintatolimod (intranasal, influenza/Ebola virus infection), Hemispherx Biopharma</Value></Name><Name><Value>38640-92-5</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="22879">Hemispherx Biopharma Inc</CompanyOriginator><CompaniesPrimary><Company id="22879">Hemispherx Biopharma Inc</Company></CompaniesPrimary><CrossReferences><SourceEntity id="22879" type="Company"><TargetEntity id="4295904158" type="organizationId">Hemispherx Biopharma Inc</TargetEntity></SourceEntity><SourceEntity id="1049" type="ciIndication"><TargetEntity id="A98.4" type="ICD10"/><TargetEntity id="078.79" type="ICD9"/><TargetEntity id="10014071" type="MEDDRA"/><TargetEntity id="D019142" type="MeSH"/><TargetEntity id="-1198952793" type="omicsDisease"/><TargetEntity id="1521" type="siCondition"/></SourceEntity><SourceEntity id="191" type="ciIndication"><TargetEntity id="J09" type="ICD10"/><TargetEntity id="10022000" type="MEDDRA"/><TargetEntity id="D007251" type="MeSH"/><TargetEntity id="948" type="siCondition"/></SourceEntity><SourceEntity id="991" type="Action"><TargetEntity id="4479" type="Mechanism">Drugs Targeting JC Polyomavirus Proteins</TargetEntity><TargetEntity id="3575" type="Mechanism">Orthopoxvirus Egress Inhibitors</TargetEntity><TargetEntity id="3235" type="Mechanism">UL29 Expression Inhibitors</TargetEntity><TargetEntity id="2893" type="Mechanism">Human T-Cell Leukemia Virus Type I (HTLV-I) Protease Inhibitors</TargetEntity><TargetEntity id="1307" type="Mechanism">Viral Fusion Inhibitors</TargetEntity><TargetEntity id="3759" type="Mechanism">L Expression Inhibitors</TargetEntity><TargetEntity id="4612" type="Mechanism">Drugs Targeting Human Immunodeficiency Virus 1 (HIV-1) Proteins</TargetEntity><TargetEntity id="3051" type="Mechanism">Viral Attachment Inhibitors</TargetEntity><TargetEntity id="5304" type="Mechanism">Drugs Targeting Rabies Virus Proteins</TargetEntity><TargetEntity id="3482" type="Mechanism">UL37 Expression Inhibitors</TargetEntity><TargetEntity id="2436" type="Mechanism">Viral Maturation Inhibitors</TargetEntity><TargetEntity id="4476" type="Mechanism">Anti-JC Polyomavirus Capsid Protein</TargetEntity><TargetEntity id="3481" type="Mechanism">UL36 Expression Inhibitors</TargetEntity><TargetEntity id="1376" type="Mechanism">BR1 Expression Inhibitors</TargetEntity><TargetEntity id="3371" type="Mechanism">Drugs Acting on Influenza Virus Proton Channels</TargetEntity><TargetEntity id="5287" type="Mechanism">Drugs Targeting Influenza Virus Proteins</TargetEntity><TargetEntity id="4128" type="Mechanism">Flavivirus Guanylyl Transferase (NS5) Inhibitors</TargetEntity><TargetEntity id="4886" type="Mechanism">Drugs Targeting Hepatitis C Virus (HCV) Proteins</TargetEntity></SourceEntity><SourceEntity id="7809" type="Action"><TargetEntity id="3107" type="Mechanism">Toll-Like Receptor 3 (TLR3) Agonists</TargetEntity></SourceEntity><SourceEntity id="PTGT-01866" type="ciTarget"><TargetEntity id="144691766170983" type="siTarget">Toll-like receptor 3</TargetEntity><TargetEntity id="-544423621" type="omicsTarget"/></SourceEntity><SourceEntity id="PTGT-08534" type="ciTarget"><TargetEntity id="9118270" type="siTarget">Polymerase cofactor VP35</TargetEntity><TargetEntity id="-1621937965" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="C2">Phase 2 Clinical</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="1049">Ebola virus infection</Indication><Indication id="191">Influenza virus infection</Indication><Indication id="6927">Zika virus infection</Indication></IndicationsPrimary><ActionsPrimary><Action id="7809">TLR-3 agonist</Action><Action id="9274">2,5-Oligoadenylate synthetase stimulator</Action><Action id="9167">Ribonuclease stimulator</Action><Action id="46991">Polymerase cofactor VP35 inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="393">Immunostimulant</Action><Action id="524">Adjuvant</Action><Action id="991">Antiviral</Action></ActionsSecondary><Technologies><Technology id="777">Nasal formulation</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="603">Systemic formulation unspecified</Technology><Technology id="103">Oligonucleotide</Technology></Technologies><EphmraCodes><Ephmra><Code>J5</Code><Name>ANTIVIRALS FOR SYSTEMIC USE</Name></Ephmra><Ephmra><Code>L3</Code><Name>IMMUNOSTIMULATING AGENTS</Name></Ephmra></EphmraCodes><LastModificationDate>2018-07-26T10:50:50.000Z</LastModificationDate><ChangeDateLast>2018-07-26T00:00:00.000Z</ChangeDateLast><AddedDate>2012-05-02T05:13:50.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="22879" linkType="Company"&gt;Hemispherx&lt;/ulink&gt; is developing rintatolimod   (Ampligen, atvogen, poly(I):poly(C12U)), a form of double-stranded RNA (dsRNA) with immunostimulatory and antiviral activity induced by activating TLR-3R, as an adjuvant delivered intranasally, for use with seasonal influenza vaccines, for the potential prevention of H5N1 avian influenza virus infection, and is also investigating the drug for the potential prevention and treatment of Ebola and Zika infection [&lt;ulink linkID="288480" linkType="reference"&gt;288480&lt;/ulink&gt;], [&lt;ulink linkID="1189246" linkType="Reference"&gt;1189246&lt;/ulink&gt;], [&lt;ulink linkID="1591517" linkType="Reference"&gt;1591517&lt;/ulink&gt;], [&lt;ulink linkID="1644540" linkType="Reference"&gt;1644540&lt;/ulink&gt;], [&lt;ulink linkID="1733565" linkType="Reference"&gt;1733565&lt;/ulink&gt;]. In April 2012, a combination  trial was initiated in the US [&lt;ulink linkID="1285361" linkType="Reference"&gt;1285361&lt;/ulink&gt;]; in December 2013, the phase I/II trial was authorized for expansion by the FDA and Data Monitoring Committee [&lt;ulink linkID="1507367" linkType="Reference"&gt;1507367&lt;/ulink&gt;]; in August 2014, results were published [&lt;ulink linkID="1593929" linkType="Reference"&gt;1593929&lt;/ulink&gt;],  [&lt;ulink linkID="1594017" linkType="Reference"&gt;1594017&lt;/ulink&gt;].   In November 2014, preclinical data for Ebola virus infection were reported [&lt;ulink linkID="1612995" linkType="Reference"&gt;1612995&lt;/ulink&gt;]. By March 2015, a clinical trial protocol was being pursued for Ebola virus infection  [&lt;ulink linkID="1644540" linkType="Reference"&gt;1644540&lt;/ulink&gt;]. In February 2016, the company was 	exploring potential uses of Ampligen against the Zika virus [&lt;ulink linkID="1733565" linkType="Reference"&gt;1733565&lt;/ulink&gt;]. In August 2017, a clinical trial of Ampligen with non-live virus vaccine was planned [&lt;ulink linkID="1953409" linkType="Reference"&gt;1953409&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Hemispherx has also developed and launched an intravenous formulation of  &lt;ulink linkID="2505" linkType="Drug"&gt;rintatolimod&lt;/ulink&gt;   for the treatment of chronic fatigue syndrome.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In March 2015, Hemispherx Biopharma Europe, a subsidiary of Hemispherx Biopharma, received a positive opinion from the EMA's COMP for Orphan Drug designation for rintatolimod for the treatment of Ebola virus disease [&lt;ulink linkID="1644540" linkType="Reference"&gt;1644540&lt;/ulink&gt;], [&lt;ulink linkID="1646151" linkType="Reference"&gt;1646151&lt;/ulink&gt;]; in April 2015, the EMA granted  Orphan Drug designation  [&lt;ulink linkID="1659555" linkType="Reference"&gt;1659555&lt;/ulink&gt;], [&lt;ulink linkID="1661864" linkType="Reference"&gt;1661864&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Influenza virus infection&lt;/subtitle&gt;In July 2011, the FDA  authorized a safety  trial of intranasal rintatolimod in combination with a seasonal influenza vaccine in healthy volunteers for influenza virus infection, including avian influenza. The trial would evaluate the breadth of immunological protection conveyed by the drug against influenza viruses. The FDA  authorization also requested for certain protocol amendments and preclinical items to be filed to the IND application [&lt;ulink linkID="1208487" linkType="Reference"&gt;1208487&lt;/ulink&gt;],  [&lt;ulink linkID="1208825" linkType="Reference"&gt;1208825&lt;/ulink&gt;]. In April 2012, the trial began. Rintatolimod was administered intranasally in combination with &lt;ulink linkID="10377" linkType="Drug"&gt;Flumist&lt;/ulink&gt; in healthy volunteers in  the US [&lt;ulink linkID="1285361" linkType="Reference"&gt;1285361&lt;/ulink&gt;]. In December 2013, the phase I/II trial was authorized for its expansion based on analysis of safety results conducted by the FDA and Data Monitoring Committee. The expanded study would include a search for immune molecules elicited by the treatment drugs which may be protective against pandemic and pre-pandemic influenza strains [&lt;ulink linkID="1507367" linkType="Reference"&gt;1507367&lt;/ulink&gt;]. In January 2014, data from the phase I/II trial were presented at the 2014 ASM Biodefense and Emerging Diseases Meeting in Washington DC. The four highest hemagglutinin (HA)-specific IgA responders demonstrated &amp;gt; 2-fold increases in IgA antibodies that cross-reacted with at least one H5 HA [&lt;ulink linkID="1518609" linkType="Reference"&gt;1518609&lt;/ulink&gt;]. In February 2013, further data presented at the 2014 ASM Biodefense and Emerging Diseases Meeting in Washington DC were reported that intranasal administration of 	Ampligen in combination with Flumist showed specific IgA antibodies against at least one of the homologous seasonal vaccine strains were elaborated in 92% of the subjects with enhanced IgA levels in healthy volunteers also and two-thirds of these recipients showed &amp;gt;/= 4-fold increase in specific IgA levels over baseline with measurable IgA levels after one year of treatment [&lt;ulink linkID="1521256" linkType="Reference"&gt;1521256&lt;/ulink&gt;]; in August 2014, similar data were published. Data demonstrated that, in phase I (n = 12) part of the trial the combination induced cross-reactive secretory IgA against HFN1, H7N9, and H7N3.  The combination was found to be well-tolerated and  the next phase was to evaluate the immunogenecity of Flumist in combination with placebo and two different doses of rintatolimod [&lt;ulink linkID="1593929" linkType="Reference"&gt;1593929&lt;/ulink&gt;],  [&lt;ulink linkID="1594017" linkType="Reference"&gt;1594017&lt;/ulink&gt;]. In August 2017, the full data analysis of the randomized, single-center, double-blind, two-stage, phase I/II study (&lt;ulink linkID="87154" linkType="Protocol"&gt;NCT01591473&lt;/ulink&gt;; AMP-600) which was initially closed, had initiated following the FDA's evaluation of preliminary reports of blinded study findings and full interim data were reported. The study enrolled 25 patients; 12 in stage one and 13 in stage two respectively. Data demonstrated that the drug was well-tolerated [&lt;ulink linkID="1953409" linkType="Reference"&gt;1953409&lt;/ulink&gt;], [&lt;ulink linkID="1954601" linkType="Reference"&gt;1954601&lt;/ulink&gt;]. In July 2018, 	filled a clinical study report with the FDA. The  report demonstrated that there was no evidence of any increase in adverse effects related to higher dosage levels of Ampligen or to the continued administration of Ampligen during the second and third dual vaccinations and was  well-tolerated and generated antibodies against influenza subtypes not present in the seasonal vaccine [&lt;ulink linkID="2052420" linkType="Reference"&gt;2052420&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2011, a phase I/II trial was planned to assess the vaccine in combination with &lt;ulink linkID="55855" linkType="Drug"&gt;NasoVax&lt;/ulink&gt; in healthy volunteers [&lt;ulink linkID="1173928" linkType="Reference"&gt;1173928&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Ebola virus infection&lt;/subtitle&gt;By March 2015, clinical trial protocol was being pursued [&lt;ulink linkID="1644540" linkType="Reference"&gt;1644540&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In February 2016, the company was 	exploring study designs for potential tests of the activity and potential uses of Ampligen against the Zika virus [&lt;ulink linkID="1733565" linkType="Reference"&gt;1733565&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2015, preclinical data from studies  in Ebola virus models, conducted by USAMRIID, were to be presented the 7th Annual International Symposium on Filoviruses in Washington, DC in March 2015. Ampligen showed  &amp;gt;2 fold survival benefit in mice compared to &lt;ulink linkID="30690" linkType="Drug"&gt;favipiravir&lt;/ulink&gt;. Ampligen reversed the relative dsRNA deficiency caused by VP35 binding of viral dsRNA [&lt;ulink linkID="1633544" linkType="Reference"&gt;1633544&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2015, preclinical data from  an ebola virus rodent study were reported. Data demonstrated that Ampligen at a dose of 400 mg resulted in 100%   survival. Higher doses  resulted a drop in the survival rate  to 90%. Mice treated with placebo had a 100% death rate by day 7 post-infection [&lt;ulink linkID="1630654" linkType="Reference"&gt;1630654&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2014, data from a research study were reported; data demonstrated that, the program had strongly inhibited the ebola minigenome in the human embryonic kidney cell system [&lt;ulink linkID="1619628" linkType="Reference"&gt;1619628&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2014,  the company identified VP35, a viral protein, as the drug target against ebola virus infection. Ampligen demonstrated antiviral activity as an IFN inducer; at that time, the epitope expansion property of Ampligen, observed in man, when applied intranasally, was  presumed to accelerate recovery from Ebola  infection [&lt;ulink linkID="1607035" linkType="Reference"&gt;1607035&lt;/ulink&gt;], [&lt;ulink linkID="1607178" linkType="Reference"&gt;1607178&lt;/ulink&gt;].  In November 2014, the USAMRIID planned to conduct in-vitro synergy studies using &lt;ulink linkID="9733" linkType="Drug"&gt;Alferon&lt;/ulink&gt; and Ampligen to demonstrate combined effect of the two drugs in both preventative and therapeutic settings of Ebola virus disease [&lt;ulink linkID="1608050" linkType="Reference"&gt;1608050&lt;/ulink&gt;].   By November 2014, data  reported that  Ampligen inhibited Ebola virus infectivity in in vitro studies with an inhibitory concentration of 4 microg/ml at 50% viral protection.   Further,  data  reported also demonstrated that Ampligen successfully bind to VP35 protein with an inhibitory concentration of 1.1 microg/ml at 50% viral protection [&lt;ulink linkID="1612995" linkType="Reference"&gt;1612995&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2014, Hemispherx planned to assess the drug against Ebola virus  [&lt;ulink linkID="1591517" linkType="Reference"&gt;1591517&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2009, it was reported that when co-administered intranasally with pandemic flu vaccines, rintatolimod may enhance immunity with higher levels of IgA and IgG in animal models and may protect against antigenic drift [&lt;ulink linkID="1048324" linkType="Reference"&gt;1048324&lt;/ulink&gt;], [&lt;ulink linkID="1049862" linkType="Reference"&gt;1049862&lt;/ulink&gt;]. Further data were reported later that month showing that rintatolimod provided cross-protective immunity against pandemic influenza variants when administered intranasally with seasonal influenza vaccines [&lt;ulink linkID="1051810" linkType="Reference"&gt;1051810&lt;/ulink&gt;], [&lt;ulink linkID="1052155" linkType="Reference"&gt;1052155&lt;/ulink&gt;]. In July 2010, similar data were reported [&lt;ulink linkID="1115561" linkType="Reference"&gt;1115561&lt;/ulink&gt;], [&lt;ulink linkID="1116451" linkType="Reference"&gt;1116451&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2007,  Japan's National Institute of Infectious Diseases, published preclinical data in The Journal of Infectious Diseases. In the study, mice were inoculated three times, intranasally  with rintatolimod and the trivalent inactivated influenza vaccine licensed in Japan for the 2005 to 2006 season. The mice were challenged with one of three strains of H5N1 influenza virus 14 days after the final injection. Results showed that intranasally inoculated mice exhibited cross-reactivity of mucosal IgA and serum IgG with H5N1 virus, indicating cross-protection against varying strains of H5N1 influenza viruses [&lt;ulink linkID="831016" linkType="Reference"&gt;831016&lt;/ulink&gt;], [&lt;ulink linkID="840950" linkType="Reference"&gt;840950&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2006, preclinical data from Japanese studies showed that  intranasal administration of  rintatolimod induced cross-protective mucosal immunity against H5N1 influenza virus infection in mice and provided protection in macaque monkeys, when combined with H5N1 vaccine. The data were presented at the Second International Conference on Influenza Vaccines for the World in Vienna, Austria [&lt;ulink linkID="733875" linkType="Reference"&gt;733875&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In October 2005, the &lt;ulink linkID="28251" linkType="Company"&gt;Japanese National Institute of Infectious Diseases&lt;/ulink&gt;  (NIID) was to investigate rintatolimod as an adjuvant in its nasal influenza vaccine [&lt;ulink linkID="626460" linkType="Reference"&gt;626460&lt;/ulink&gt;]. In September 2007, the Japanese NIID expanded the agreement to include studies of rintatolimod with its intranasal HIV-1 vaccine [&lt;ulink linkID="829253" linkType="Reference"&gt;829253&lt;/ulink&gt;]. In December 2007, Biken (operational arm of the &lt;ulink linkID="30063" linkType="Company"&gt;Foundation for Microbial Diseases of Osaka University&lt;/ulink&gt;) non-exclusively licensed &lt;ulink linkID="22879" linkType="Company"&gt;Hemispherx&lt;/ulink&gt;' rintatolimod as an adjuvant in its &lt;ulink linkID="56471" linkType="Drug"&gt;influenza vaccines&lt;/ulink&gt;. Hemispherx would receive royalties and income from rintatolimod used in experimental work, as well as any commercialization of the drug as an adjuvant in intranasal flu vaccines in Japan. This deal is part of a three party agreement to develop a Japanese influenza vaccine and includes the NIID [&lt;ulink linkID="860824" linkType="Reference"&gt;860824&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Rintatolimod consists of poly I:poly C12U RNA strands. As a dsRNA, rintatolimod is able to mimic the action of interferons. The first step, activation of 2,5-oligoadenylate (2,5-A) synthetase, ultimately leads to activation of RNase-L, which destroys viral RNA preferentially. Additionally, 2,5-A controls the growth of certain human tumor cells [&lt;ulink linkID="288484" linkType="reference"&gt;288484&lt;/ulink&gt;], [&lt;ulink linkID="288495" linkType="reference"&gt;288495&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="22879">Hemispherx Biopharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="191">Influenza virus infection</Indication><StatusDate>2011-03-07T00:00:00.000Z</StatusDate><Source id="1173928" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22879">Hemispherx Biopharma Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1049">Ebola virus infection</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1646151" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22879">Hemispherx Biopharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1049">Ebola virus infection</Indication><StatusDate>2014-09-08T00:00:00.000Z</StatusDate><Source id="1591517" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22879">Hemispherx Biopharma Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="191">Influenza virus infection</Indication><StatusDate>2006-03-15T00:00:00.000Z</StatusDate><Source id="655922" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22879">Hemispherx Biopharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="6927">Zika virus infection</Indication><StatusDate>2016-02-09T00:00:00.000Z</StatusDate><Source id="1733565" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="22879">Hemispherx Biopharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="191">Influenza virus infection</Indication><StatusDate>2011-07-19T00:00:00.000Z</StatusDate><Source id="1208487" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="22879">Hemispherx Biopharma Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="1049">Ebola virus infection</Indication><AwardedIndication>Treatment of Ebola virus disease</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2015-04-24T00:00:00.000Z</MileStoneDate><Source id="1661864" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="22879">Hemispherx Biopharma Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="1049">Ebola virus infection</Indication><AwardedIndication>Treatment of Ebola virus disease</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2015-03-19T00:00:00.000Z</MileStoneDate><Source id="1646151" type="PR"/></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-01690"><Name>Ribonuclease</Name><SwissprotNumbers/></Target><Target id="PTGT-01866"><Name>TLR-3</Name><SwissprotNumbers><Swissprot>O15455</Swissprot><Swissprot>Q99MB1</Swissprot></SwissprotNumbers></Target><Target id="PTGT-02129"><Name>2,5-Oligoadenylate synthetase</Name><SwissprotNumbers/></Target><Target id="PTGT-08534"><Name>Polymerase cofactor VP35</Name><SwissprotNumbers><Swissprot>P35259</Swissprot><Swissprot>Q03039</Swissprot><Swissprot>Q05127</Swissprot><Swissprot>Q1PD52</Swissprot><Swissprot>Q1PDC9</Swissprot><Swissprot>Q5XX07</Swissprot><Swissprot>Q6UY68</Swissprot><Swissprot>Q6V1Q9</Swissprot><Swissprot>Q8JPY0</Swissprot><Swissprot>Q91DE0</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1031352">National Institute of Biomedical Innovation</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1059959">Japan's Council for Science &amp; Technology Policy</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1127232">Avrio Biopharmaceuticals LLC</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1137216">Swiss Department of Defense</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20516">US Government</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="20653">Osaka University</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="22879">Hemispherx Biopharma Inc</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>6</CountTotal></Company><Company><Company id="28251">National Institute of Infectious Diseases Japan</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="10">Technology - Other Proprietary</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="3">Drug - Early Research/Development</Type><CountActive>3</CountActive><CountInactive>0</CountInactive><CountTotal>3</CountTotal></Type><Type><Type sortOrder="6">Drug - Manufacturing/Supply</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="7">Drug - Development Services</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles/><Deals><Deal id="111072" title="Biken to use Hemispherx's Ampligen as an adjuvant in its influenza vaccines in Japan "/><Deal id="123983" title="NIID to investigate Hemispherx Biopharma's Ampligen as an adjuvant in its nasal influenza vaccine       "/><Deal id="124585" title="CSTP to award NIBIO funding for research in influenza vaccines using Hemispherx's Ampligen as an adjuvant "/><Deal id="150768" title="US Government to test Hemispherx Biopharma's Alferon and Ampligen against Ebola virus          "/><Deal id="161644" title="Avrio Biopharmaceuticals' to manufacture Hemispherx's Ampligen         "/><Deal id="167153" title="Research collaboration to conduct clinical tests for Alferon N Injection for tamiflu resistant influenza virus infection"/><Deal id="167362" title="Research collaboration to study Alferon and Ampligen for Ebola virus infection"/></Deals><hasSWOTs>N</hasSWOTs></drugRecordOutput>